Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiary, Guangzhou Baiyunshan Chen Li Ji Pharmaceutical Factory, received the Chinese drug administration's approval to conduct clinical trials on the Yupingfeng tea bag, according to a Shanghai Stock Exchange filing on Wednesday.
The product will be tested as a treatment for Hashimoto's thyroiditis, subclinical hypothyroidism and clinical hypothyroidism patients who exhibit symptoms of spleen and lung Qi deficiency after LT4 treatment, the pharmaceutical company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.